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Abstract
Thirty-five U.S. states and territories have implemented policies requiring insurers to cover patient
care costs in the context of cancer clinical trials; however, evidence of the effectiveness of these
policies is limited. This study assesses the impact of state insurance mandates on clinical trial
accrual among community-based practices participating in the NCI Community Clinical Oncology
Program (CCOP), which enrolls approximately one-third of all NCI cancer trial participants. We
analyzed CCOP clinical trial enrollment over 17 years in 37 states, 14 of which implemented
coverage policies, using fixed effects least squares regression to estimate the effect of state
policies on trial accrual among community providers, controlling for state and CCOP differences
in capacity to recruit. Of 91 CCOPs active during this time, 28 were directly affected by coverage
mandates. Average recruitment per CCOP between 1991 and 2007 was 95.1 participants per year
(SD = 55.8). CCOPs in states with a mandate recruited similar numbers of participants compared
to states without a mandate. In multivariable analysis, treatment trial accrual among CCOPs in
states that had implemented a coverage mandate, was not statistically different than accrual among
CCOPs in states that did not implement a coverage mandate (β = 2.95, p = 0.681). State mandates
did not appear to confer a benefit in terms of CCOP clinical trial accrual. State policies vary in
strength, which may have diluted their effect on accrual. Nonetheless, policy mandates alone may
not have a meaningful impact on participation in clinical trials in these states.
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Although one third of U.S. adults say they would participate in cancer clinical trials given
the opportunity, only 2.5 to 5% of eligible adults are successfully recruited [1-2]. The
consequences are serious: low recruitment limits generalizability of trial results, threatens
trial completion, and, ultimately, delays the development and availability of potentially
beneficial new therapies. Among multiple patient, trial, provider, and health system
characteristics associated with low participation [3], one long-cited barrier to enrollment is
insurance coverage: Eight to 20% of eligible patients decline to participate in trials because
of potential denial of coverage [4-6]. Although study sponsors typically cover the cost of
experimental therapy and patients incur treatment costs regardless of trial participation,
insurers are thought to refuse coverage for any treatment provided in the context of a clinical
trial [7-10]. Subsequently, potential participants may not be willing to participate in trials
when reimbursement for their care is jeopardized.
Since 1995, advocates have successfully lobbied for policy changes that ensure care
coverage, culminating in the inclusion of a national mandate in the Patient Protection and
Affordable Care Act, slated for implementation in 2014 [11-12]. Currently, 35 states and
territories and the Centers for Medicaid and Medicare Services (CMS) have active policies
mandating coverage of non-research costs for covered patients [13]. The impact of these
policies on trial participation has not been demonstrated definitively, with studies of federal
and state policies showing mixed results [14-18].
Results of state policy studies have been most promising. One single-state, uncontrolled
comparison of participation before and after policy enactment showed an increase in trial
participants and a simultaneous decrease (to zero) in the number of decliners citing
insurance reimbursement fears as the reason for non-participation [17]. Another single-
institution study found more frequent insurance denials among eligible participants in a state
without an insurance mandate than in two states with mandates [19]. A third early
assessment found an increase in accrual among NCI-sponsored phase II (but not phase III)
trials in four states that had enacted mandates, compared to states with no such policies [18].
Since these earlier studies, state mandates have more than doubled. However, no studies to
date have examined the effects of the mandates on enrollment in the community, where the
majority of patients receive their cancer care [20].
The Community Clinical Oncology Program (CCOP) is a network of mostly non-academic
hospitals and oncology practices throughout the U.S., funded by the National Cancer
Institute (NCI) to provide infrastructure for community-based trial recruitment.
Approximately one-third of research participants recruited to NCI trials are recruited by
CCOP sites [21-22]. Between 1991 and 2007, 98 CCOPs were funded in 39 states and
territories. This study analyzes a 17-year, longitudinal multi-state dataset of NCI-sponsored
cancer clinical trial enrollment to examine the effect of state policies mandating clinical trial
coverage on treatment trial accrual among community practices responsible for a substantial
portion of recruitment to NCI cancer trials.
Methods
This analysis uses state-level fixed effects least squares estimation to determine the impact
of state clinical trial coverage mandates on treatment trial accrual among CCOPs, while
controlling for multiple time-varying and time-invariant factors associated with trial
enrollment. This approach, with fixed effect estimation and examination of a long baseline
period, allows for better isolation of the policy effect than traditional methods.
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The analytic dataset is derived from a secondary, unbalanced panel dataset created to
evaluate the performance and sustainability of the NCI CCOP program. The study dataset
represents the full population of CCOPs and includes CCOP-level characteristics and state-
level factors describing the CCOP environment and associated with CCOP performance.
Publicly available state policy information was abstracted from the NCI State Cancer
Legislative Database, supplemented with details from the American Cancer Society and
published research [10, 13, 23-24]. In 2007, new Institute of Medicine cancer clinical trial
restructuring recommendations went into effect, limiting the number of trials offered, so
data is restricted to the 17 years of data available prior to 2008. One CCOP, Southeast
Cancer Control Consortium, was excluded from analysis because it is made up of oncology
practices in multiple states and we were unable to attribute accrual to its individual state-
specific components. After this exclusion, 97 unique CCOPs were represented during the
years 1991-2007. CCOP enrollment occurred in waves, so 1079 CCOP-year observations
were available for analysis.
Measures
CCOPs recruit patients to both cancer treatment and cancer prevention and control
protocols. However, state policies mandate coverage of patient care costs and would be
unlikely to affect prevention efforts occurring outside the context of the healthcare system
[25]. Therefore, this analysis focuses on treatment trial accrual, measured as a count of the
number of patients each CCOP recruited to treatment clinical trials each year.
The explanatory variable of interest is a binary variable representing the presence of a
cancer clinical trial policy in a state in each year following its implementation. Also
included in the consideration of state mandates are any statewide formal voluntary
agreements among insurers to cover care in the context of cancer clinical trials. Four states
have such agreements: Georgia, Michigan, New Jersey and Ohio.[13] We used
implementation date, rather than passage date as the date of interest. For policies
implemented January 1 through June 30 of any year, we considered the policy implemented
in that year. For policies implemented July 1 through December 31, we considered the
policy implemented in the next calendar year, providing opportunity for behavior change to
take effect.
Clinical trial recruitment is expected to change over time for factors unrelated to state
policies or the CCOP characteristics included in the model. Thus, a set of dummy variables
indicating calendar years is included to capture changes in accrual over time, such as
changes in national trial availability and the national Medicare Coverage Determination
signed by President Bill Clinton in 2001 and implemented across all states [24], among other
global trends.
Other control variables include CCOP characteristics representing the recruiting potential of
each organization. We controlled for a program’s participation as a Minority-based CCOP
(MBCCOP). MBCCOPs are specially organized programs designed to enhance minority
participation in cancer research [26]. While successful in their mission, these CCOPs face
distinct recruitment challenges, including both the environments in which they recruit as
well as the populations they target, who may be more reluctant to participate in research
[26-27].
The remaining control variables account for each CCOP’s size and productive capacity.
Each CCOP is made up of multiple hospitals and community oncology practices. The
greater number of sites from which a CCOP draws will directly influence its accrual.
Likewise, the number of physicians who recruit for each CCOP is an indicator of the size
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and clinical diversity of the patient base from which a CCOP draws its clinical trial
participants [28]. We assessed appropriate functional form of the continuous variables by
comparing the adjusted R2 of models with alternative forms to the models with the original
term. A quadratic form was shown to be the best characterization of the number of
physicians accruing patients. A three-knot spline of four equal percentiles was chosen for
the number of components.
Statistical Analysis
We compared pooled ordinary least squares, state fixed effects and random effects models
for appropriate model fit. Specification tests, including an F-test of the joint significance of
the fixed effects dummy intercepts, a Breusch-Pagan Lagrangian Multiplier test, and the
Hausman test, indicated that the fixed effect model was most appropriate [29]. We used
complete case analysis to address missing data.
Sensitivity Analyses—We made several assumptions in specifying our model, which
required explicit review and assessment. Several CCOPs recruit participants across state
lines, due to either geographic proximity (e.g., Kansas City, MO site lies on the border of
Kansas and Missouri) or contractual arrangement. We reviewed each of these sites to assess
whether they potentially recruited patients from states that had discordant policies from the
state in which the CCOP was headquartered. For three of the sites, the policies were the
same in the state in which the CCOP was headquartered and that state in which they
recruited small numbers of patients: for each pair, both states had no cancer trial mandate.
For two sites, state policies differed in the two jurisdictions from which participants were
potentially drawn.
In addition, pediatric recruitment is known to be quite different from adult recruitment. For
example, approximately half of children ages 5 to 9 are recruited to cancer trials compared
to 1% of adults ages 75 to 79 [2]. We identified one CCOP that recruited exclusively for
pediatric trials.
The requirements and breadth of policies vary among states [24], thus we also assessed a
measure of policy strength by assigning a single score to each state, which assigned one
point for each phase of trial covered (I-III) and one point for each payer type required to
provide coverage, as these aspects should have most directly affected treatment trial accrual.
We also were concerned that clinical trial recruitment in more recent decades may be
fundamentally different than that in the 1990s due to changes in healthcare payment [22].
Thus, we conducted a Chow test for structural differences in treatment accrual and a
sensitivity analysis restricted to the years 2001 through 2007 to assess whether our model
was robust, finding that the two periods were structurally similar and could be pooled. We
also thought it important to assess potential bias induced by not controlling for varying
levels of uninsured residents among the states.
Subsequently, a number of sensitivity analyses were conducted, repeating analyses after: 1)
removing CCOPs which potentially recruit participants from states with discordant policies;
2) removing CCOPs which recruit only pediatric patients; 3) substituting a policy strength
score for the binary indicator of mandate implementation; 4) restricting data to 2001-2007;
and, 5) including the proportion of uninsured patients in the metropolitan statistical area
surrounding each CCOP in this more recent time period.
Two-sided tests of statistical significance were used to assess the significance of regression
coefficients. Heteroskedasticity of the model was indicated by the Breusch-Pagan test for
heteroskedasticity [29]. Thus, Huber-White cluster robust standard errors are used. All
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analyses were conducted in Stata 11.2 [30]. The University of North Carolina, Chapel Hill
Institutional Review Board deemed the study exempt from review.
Results
The final sample of 883 observations consisted of 85 CCOPs across 37 states and U.S.
territories. Of the 37 states and territories represented, 14 states implemented a policy during
the study period; 23 did not. One state (Illinois) allowed its mandate to expire [24] and
CCOPs in two states closed (and thus their states dropped from the dataset), one before its
state policy was implemented (see Figure 1). In total, 13 states contributed data both before
and after policy implementation. Policy implementation occurred between 2000 and 2007.
Figure 2 illustrates state policy implementation trends among states with CCOPs. Forty-
three CCOPs were in states that implemented policies, and 28 were actively participating
when the policy went into effect.
Table 1 shows descriptive statistics for the full sample and by presence of a state coverage
mandate. Mean recruitment overall was 95.1 participants per year, with a range of 0 to 411.
CCOPs in states with a mandate recruited fewer participants, although the difference was
not statistically significant. Minority CCOP status did not vary by policy status. Compared
to states with mandates, there were significantly fewer physicians participating in each
CCOP per year in states without, or prior to mandated coverage, and fewer components per
CCOP in the lowest quartile of CCOP components in states with the policy. Sites with
missing data had significantly fewer accruals (68.63 vs. 95.08, p<0.001), lower rates of
policy exposure (0.01 vs. 0.14, X2 = 14.54, p<0.001), and fewer physicians recruiting
patients (9.35 vs. 16.96, p<0.001), though they had similar numbers of components (4.38 vs.
5.48, p=0.13).
Recruitment fluctuated over time in both policy states and non-policy states (Figure 3). In
the early 2000s as mandates were beginning to be implemented, gaps in average accrual
between the policy states and non-policy states tightened; however, the effect was similar in
size to the smallest gaps in the 1990s and the tightening did not last beyond 2003, even as
additional states implemented coverage policies. Of the 13 states with accrual data before
and after implementation, there was no significant difference in accrual in the two time
periods for nine states. One state had a statistically significant drop in accrual and three
states had a statistically significant increase in accrual.
Table 2 presents findings from the state fixed effects analysis. After adjusting for accrual
trends over time, minority CCOP status, the number of physicians recruiting, the number of
components per CCOP, and state characteristics, CCOP treatment trial accrual in states with
a coverage mandate was not significantly different than in states with no such mandate.
As expected, minority-based CCOPs were associated with less trial accrual, 27.0 fewer
participants, all else equal. The marginal effect of the number of physicians recruiting was
an additional 2.3 participants recruited per year (95% CI 1.6, 3.0) which was statistically
significant. The number of components in a CCOP positively influenced recruitment rates,
but only at the highest quartile. Enrollment increased over time (p<0.001), suggesting that
other factors that changed over time were important in influencing CCOP accrual.
Findings did not differ meaningfully among the multiple sensitivity analyses examining
different sample or model assumptions. Specifically, excluding CCOPs with multi-state or
pediatric enrollment or limiting the study to the post-Medicare mandate also produced non-
significant point estimates of the effect of state policy. Replacing the explanatory variable of
interest with a crude policy strength index and including the proportion of uninsured in the
limited time period both provided a non-significant policy effect as well.
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In this analysis, state policies mandating cancer clinical trial coverage were not associated
with differences in accrual to NCI clinical treatment trials among a diverse national group of
community cancer centers. Although a few states saw gains in recruitment after policy
implementation, most did not and there was no net effect of state policies.
These findings differ from earlier results, which showed greater accrual in at least some
types of trials following state policy implementation [17-18]. By design, our study excluded
academic centers and Veterans Administration (VA) sites that may have a different
experience [6], and specifically examined accrual in the community setting where the
majority of cancer patients receive treatment. Prior research examining academic centers or
both community and academic centers showed positive effects [17] or mixed results [18] of
such policies. We can think of no reason why insurance mandates would be more effective
in academic sites than in community sites. In fact, mandates are more likely to enhance
recruitment at community sites: Many mandates allow insurers to deny coverage of patient
care costs when they are out of network [8] and because most patients have greater access to
the more geographically dispersed community sites, academic medical centers are more
likely to be out of network. Insurance mandates should have little or no effect on VA
recruitment since the VA serves as both payer and provider.
There are a number of reasons why these policies may not be effective. Insurance concerns
may be less of a barrier to recruitment than assumed. Although anecdotal evidence exists in
the popular press and from within the ranks of experienced trial administrators [5-6], actual
instances may be rare and reflect more of the exception rather than the rule of insurer
practices, though they may generate a disproportionately negative perception among
prospective trial participants. Individuals’ refusal to participate due to fear of coverage loss
is low, cited by only 8% of refusers [4]. Further, 8% of patients denied coverage actually do
participate [6]. From 80% to 85% of claims for treatment on clinical trial are ultimately paid
[6, 31]. Additionally, payers’ policies on coverage of trials reportedly have begun favoring
coverage since the early 2000s [32]. Trial participation rates increased among the privately
insured between 1996 and 2001 [18]. It also may be that the majority of insurers actually do
provide coverage—either as a matter of policy or unwittingly. While there is evidence that
claims are denied when insurers are told that care is part of a clinical trial [19], it is often
difficult to distinguish whether care is part of one and thus, insurers may pay for it,
regardless of internal policies [8]. Ultimately, insurance coverage is only one potential
barrier to participation in clinical trials. Only about 20% of cancer patients meet eligibility
criteria for clinical trials and physicians may not even offer all eligible patients trial
participation for a number of reasons [5]. Consequently, coverage concerns may be
overshadowed.
This study used more recent data, incorporated more state policies, and made use of
longitudinal data and estimation techniques that address selection bias. Our study design
included lengthy baseline assessment to capture trends over time and the panel design
allowed us to compare both within-state changes in accrual before and after mandate
implementation among policy states and differences in accrual between mandate and non-
mandate states. Nonetheless, a number of factors may have limited our ability to detect an
effect, if there is one, including data availability, competing policies, and policy dilution.
Although we examined data for nearly all CCOPs in existence, spanning 17 years of trial
enrollment, the study question mandated a data structure and approach that yielded relatively
few observations (CCOP-years) for a multivariable examination. The limited observations,
with correspondingly limited variance among the key variables, may have functionally been
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too small to yield a statistically detectable policy effect. Related to this, although selection
of variables was driven by theory and practical knowledge, the limited effective sample size
obliged us to be parsimonious in variable selection, and there may be other important
variables for inclusion. For example, health insurance access, theoretically should be a
relevant factor; however, in other analyses of these data, correlation between an area’s
proportion of uninsured and accrual was low, and it was not a significant predictor of
accrual [28]. In this sample, there was no difference in the average proportion uninsured
between mandate and non-mandate states. Moreover, sensitivity analysis including this
variable in the model showed no difference in the effect of state policy. Because the change
in the proportion of uninsured per area measured is quite small from year to year, we believe
it essentially is controlled for by the state fixed effect. Future research may overcome these
challenges through a multi-level examination including person-level enrollment and
additional relevant variables. For example, age is relevant for several reasons, including trial
eligibility and age-related non-participation [33].
We cannot be certain that data availability did not limit our ability to detect an effect of state
policies. Missing data and misclassification may have biased our results. Four CCOPs with
missing data were excluded from the analysis, and some bias might have been introduced
since missing data was associated with trial accrual and state policies. However, this would
suggest our results overestimate the policy effect size and would not change our
conclusions.
Competing policies also may have introduced noise and diluted our ability to detect the
effect of state policies. For example, while our study focused on state policies, a series of
federal policies were passed over the last decade to facilitate clinical trial participation. In
particular, a 2000 executive order (later expanded) required Medicare to reimburse for
routine care associated with trial participation [5, 16]. By including a measure for time in
our analysis, we adjusted for such effects by controlling for trends that affected both
mandate and non-mandate states. However, if this policy was implemented unevenly, as has
been reported [8], our ability to control for it through the method would be limited. In our
sample, it appears a change occurred after 2001 in both mandate and non-mandate states
(Figure 3), limiting concerns that uneven implementation biased results.
Of some concern is that state laws may only affect as little as a third of the population
because of federal exemptions for some employers. The Employee Retirement Security
Income Act (ERISA) exempts some self-insured employer-sponsored plans from the state
mandates, affecting about 67 million Americans [8]. We are unable to assess how
distribution of these plans across states affects clinical trial accrual. As long as the
distribution of ERISA plans remains constant over time within state, we have effectively
controlled for them by including state fixed effects, but any changes in concentrations of
self-insured employers in any state may bias the effect of state policies.
Finally, state policies mandating trial coverage vary in scope [24]. All require private
insurers to cover trial costs, but some states additionally require certain government
sponsored plans to participate [13, 24]. Nine states (18%) require coverage for all four
phases of clinical trials, but other states specify that only certain phases of research qualify
[24, 34]. The effect of mandated coverage of research-related injuries on trial participation is
unknown, but some states additionally require it [24]. In addition, several states have
voluntary agreements rather than statutes [8] and it is unknown whether these agreements
have similar implementation rates as official policies. This variability among the policies
could significantly impact our ability to estimate their effectiveness. We attempted a crude
analysis of policy strength. We found no difference in our results. Results are not presented
as we have concerns about the scale’s validity. We do not know if the weights given to each
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dimension are appropriate, nor if the effects of various components of the mandates are
additive or multiplicative. Moreover, the mandates include other important coverage
requirements such as coverage of research-related injuries [24] and the relative contributions
of these requirements is unknown. An index that more appropriately weights all aspects of
the provisions, including the relative effect of coverage of research-related injury and trial
phases, is needed. Thus, future research should characterize fully the strength of each state’s
policy, including identifying incremental changes in patients’ willingness to participate with
each coverage stipulation; understanding the effects of seemingly non-complementary
provisions; and, psychometrically testing a summary index. Other research should further
evaluate how dissemination of information about the state mandates, and enforcement of
them, additionally contributes to their strength. Dissemination of these policies to potential
participants has been shown to be weak [31]. Greater differences may have been evidenced
had potential participants been aware of them.
Conclusions
This study highlights many of the challenges to the effectiveness and evaluation of state-
level policies, some of which the 2014 federal policy mandate will address. Nonetheless,
developing and implementing such policies is resource intensive and represents an
opportunity cost. Addressing lower-level factors not easily reached by policy interventions
may be more fruitful. Research infrastructure is associated with physician participation in
research [35] and on-site physician champions have been shown to sustain high accrual
[36-37]. Efforts that directly support physician leaders and the physicians in research-
supportive environments who do not participate in research [35] may more efficiently
enhance accrual. Recent experience among the CCOP suggests that as stand-alone hospitals
evolve into health systems, even greater interest exists to integrate research into the clinical
mission, presenting opportunity to increase access to trials. Thus, interventions which
support and protect interests of research participants in the context of this new delivery
landscape, hold promise and require investigation. Understanding the practical challenges at
the individual-, provider-, or health system-level are still necessary to ultimately encourage
cancer patients to participate in clinical research. Whether these interventions can be
delivered effectively through policy or through other mechanisms remains unanswered.
Although our results do not provide encouragement that state mandates improve community
accrual, coverage policies warrant continuing assessment. Continued vigilance and ongoing
communication with third party payers to assure high quality care and an environment that
promotes scientific discovery in an efficient manner is still needed. Third party coverage of
experimental therapies may keep potential participants from joining trials and lure
participants off of protocols if their preferred treatment is covered outside the context of
clinical trials [5, 38]. Continued efforts to partner with payers to facilitate trial participation
will allow patients who want to participate to have the opportunity and payers to have the
best evidence-based information upon which to base their coverage policies. Finally, even if
these policies do not have an effect on trial accrual, they may serve other purposes such as
increasing minority participation in clinical trials [10, 39] and ensuring providers are paid
for their efforts and experience less burden and administrative costs, encouraging their
continued participation, a necessary part of ensuring future trial availability [8, 40]. These
additional potential outcomes are equally important and deserve to be assessed.
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Figure 1. Policy states and CCOPs remaining in final year of study, 2007
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Figure 2. Number of states with policy mandates in study sample
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Figure 3. Average treatment trial accrual by year
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Table 1
CCOP-Year Descriptive Characteristics by State Policy Implementation












Percent Observations with State
Coverage Mandate
13% 0% 100%
Percent Observations Per Year
   1991 6% 7%** 0%
   1992 4% 5%** 0%
   1993 4% 5%** 0%
   1994 6% 7%** 0%
   1995 6% 7%** 0%
   1996 6% 7%** 0%
   1997 6% 7%** 0%
   1998 5% 6%** 0%
   1999 5% 6%** 0%
   2000 6% 6% 7%
   2001 6% 6% 8%
   2002 7% 5%*** 14%
   2003 7% 6%** 13%
   2004 7% 6%*** 14%
   2005 7% 6%** 13%
   2006 7% 5%*** 15%
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Mean (SD) Mean (SD) Mean (SD)
Percent Observations Per Region
   Northeast 12% 13%** 5%
   South 24% 23%* 31%
   West 19% 18% 20%
   Midwest 44% 43% 44%
n=883 CCOP-years n=749 CCOP-years n=134 CCOP-years
Statistical significance reflects comparison of states without a mandate to states with a mandate
*
statistically significant at p<0.05
**
statistically significant at p<0.01
***
statistically significant at p<0.001 continuous variables compared with t-test assuming equal variances
¥
continuous variables compared with t-test assuming unequal variances dichotomous variables compared with Pearson’s Chi-square
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Table 2
State Fixed Effects Regression Model Results
β 95% CI
State Coverage Mandate 2.95 −11.48, 17.38
Year (referent 1991)
   1992 −4.35 −10.66, 1.96
   1993 −12.97** −21.98, −3.95
   1994 −14.77** −23.63, −5.91
   1995 −14.33** −23.45, −5.20
   1996 −4.73 −16.98, 7.51
   1997 6.61 −4.32, 17.55
   1998 13.81* 1.48, 26.14
   1999 10.83 −3.03, 24.69
   2000 13.05 −0.25, 26.36
   2001 16.34* 2.94, 29.74
   2002 −4.69 −17.87, 8.50
   2003 −7.41 −20.26, 5.44
   2004 16.10* 1.57, 30.63
   2005 25.04** 8.10, 41.98
   2006 1.55 −10.55, 13.65
   2007 4.31 −9.91, 18.52
Minority-base CCOP −27.06** −43.07, −11.06
Number of MDs Participating 3.11*** 2.00, 4.23
Number of MDs Squared −0.02** −0.04, −0.01
Number of Components:1-25th percentile 2.43 −6.36, 11.22
Number of Components: 26-50th percentile 0.51 −5.86, 6.88
Number of Components: 51-75th percentile 0.78 −8.41, 9.98
Number of Components: 76-100th percentile 4.05*** 1.99, 6.12
Region (referent Midwest)
   Northeast¥ --
   South¥ --
   West¥ --
Constant N 40.85** 15.86, 65.84 883
N 883
95% Confidence Intervals calculated with Huber-White robust standard errors
*
statistically significant at p<0.05
**
statistically significant at p<0.01













Ellis et al. Page 18
***
statistically significant at P<0.001
¥
Time-invariant at the state level, not estimated in state fixed effect model
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